Leqembi Iqlik

← The FDA Ephemeris: the whole map

Leqembi Iqlik lecanemab-irmb, subcutaneous

Queued: 4 FDA documents (141 pages) are in the system, waiting to be read into the graph.

Application: BLA 761375
Sponsor: Eisai
Drug class: Anti-amyloid antibody
First approved: August 29, 2025

FDA decisions

August 29, 2025 Leqembi Iqlik, subcutaneous maintenance Subcutaneous maintenance dosing
July 13, 2026 Leqembi Iqlik, subcutaneous initiation Subcutaneous initiation dosing

Also anti-amyloid antibodys: Aduhelm, Leqembi, Kisunla

From FDA documents. Not medical advice.

Anti-amyloid antibody

Aduhelm aducanumab-avwa
Leqembi lecanemab-irmb
Kisunla donanemab-azbt
Leqembi Iqlik lecanemab-irmb, subcutaneous

Regulatory records

Cholinesterase inhibitor

Cognex tacrine hydrochloride
Aricept donepezil hydrochloride
Exelon rivastigmine tartrate
Razadyne galantamine hydrobromide
Aricept ODT donepezil hydrochloride
Razadyne ER galantamine hydrobromide
Adlarity donepezil hydrochloride
Zunveyl benzgalantamine gluconate

NMDA receptor antagonist

Namenda memantine hydrochloride
Namenda XR memantine hydrochloride

Amyloid PET imaging agent

Amyvid florbetapir f-18
Vizamyl flutemetamol f-18
Neuraceq florbetaben f-18

Combination

Namzaric donepezil hydrochloride; memantine hydrochloride

Atypical antipsychotic

Rexulti brexpiprazole

Tau PET imaging agent

Tauvid flortaucipir f-18

Group by

Build queue · replay at pipeline speed